# Soligenix, Inc > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/Soligenix, Inc). ## Overview Soligenix, Inc. is a U.S.-based late-stage biopharmaceutical company focused on developing and commercializing therapies for rare diseases and other conditions with unmet medical need. Its pipeline is organized into two business segments: Specialized BioTherapeutics and Public Health Solutions, with programs spanning photodynamic therapy, inflammatory disease, and biodefense-related medical countermeasures. ## Products & services • HyBryte™ (SGX301) for cutaneous T-cell lymphoma • SGX302 for psoriasis • Dusquetide programs: SGX942 and SGX945 • Public health and biodefense product development • Government-funded clinical research and subawards - **Specialized BioTherapeutics** (85%) — Clinical-stage therapies for rare diseases and inflammatory conditions, including HyBryte™, SGX302, SGX942 and SGX945. - **Public Health Solutions** (15%) — Programs and collaborations tied to public health, biodefense, and government-supported development work. - HyBryte™ (SGX301) for cutaneous T-cell lymphoma - SGX302 for psoriasis - Dusquetide programs: SGX942 and SGX945 - Public health and biodefense product development - Government-funded clinical research and subawards ## Customers Soligenix does not sell to a broad commercial customer base in the way a mature pharmaceutical company does; its primary counterparties are clinical trial participants, research collaborators, government agencies, and potential future commercial partners. In the current stage of the business, value is created through development programs, grant-funded work, and eventual licensing or commercialization of approved therapies. - **Clinical trial patients** (primary) — Patients with CTCL, psoriasis, oral mucositis, Behçet's disease, and related rare/inflammatory conditions enrolled in studies of the pipeline. - **Government and grant funding bodies** (primary) — Public agencies and programs that support development work through grants, subawards, and research contracts. - **Potential commercial partners** (secondary) — Biopharma partners that may license, co-develop, or help commercialize product candidates after clinical success. - **Specialty physicians and treatment centers** (secondary) — Future end users for approved therapies in dermatology, oncology, and inflammatory disease settings. - Patients enrolled in clinical trials for rare disease therapies - Government agencies funding research and development subawards - Potential pharmaceutical partners for licensing or commercialization - Clinical investigators and trial sites supporting studies - Future prescribers and specialty treatment centers if products are approved ## Geography Soligenix is headquartered in the United States and conducts its development activities through a U.S.-based biopharmaceutical structure. Its programs are intended for worldwide regulatory pathways, including the U.S. FDA and the European Medicines Agency, so clinical and commercialization exposure is tied to both U.S. and international approval processes. - Headquartered in the United States - Clinical development and corporate operations are U.S.-based - Regulatory pathway includes FDA and EMA review - Potential commercialization is intended to be worldwide - Foreign regulatory requirements affect trial design and approval timing ## Strategy The company’s strategy is to advance HyBryte™ through late-stage clinical development and seek regulatory approval for CTCL, while extending its synthetic hypericin platform into adjacent indications. It also pursues government support, partnerships, and other financing sources to fund development and preserve optionality across its pipeline. - **Complete late-stage development of HyBryte™** (medium-term) — Regulatory approval depends on successful confirmatory clinical data in CTCL. - **Broaden the synthetic hypericin platform** (medium-term) — Additional indications can increase the value of the core technology beyond CTCL. - **Advance dusquetide-based inflammatory disease programs** (medium-term) — Pipeline diversification reduces dependence on a single lead asset. - **Secure external funding and partnerships** (short-term) — Development-stage biopharma programs require non-dilutive support and collaboration capital. - Advance HyBryte™ through confirmatory Phase 3 development - Expand synthetic hypericin into additional indications - Develop dusquetide programs for inflammatory diseases - Pursue government grants and subawards for funding support - Seek partnerships and strategic transactions for pipeline value ## Risks Soligenix faces the typical risks of a development-stage biopharmaceutical company: clinical trial failure, regulatory delay, manufacturing dependence, and competition from alternative therapies. Company-specific risks also include dilution from equity-linked securities and dependence on external financing to support ongoing development and operations. - **Clinical development failure** [critical] — Pipeline value depends on positive trial outcomes, especially for HyBryte™ and other candidates. - **Regulatory approval risk** [high] — Products cannot be commercialized without FDA/EMA approval and the company has limited approval experience. - **Manufacturing and supply chain dependence** [high] — Clinical and commercial supply relies on third-party manufacturers meeting quality and timing requirements. - **Financing and dilution risk** [high] — Development spending exceeds current product revenue and the company relies on external capital sources. - **Competitive and technology risk** [medium] — Other companies may develop more effective or better-tolerated treatments for the same indications. - Clinical trials may fail to show safety or efficacy - Regulatory approval is uncertain and can be delayed - Manufacturing partners may not supply compliant product on time - Competition may produce superior therapies - Financing needs can drive dilution and capital structure risk ## Accounting The most important accounting issues are fair value measurement of debt and equity-linked instruments, as well as the treatment of grant- and subaward-related revenue. Because the company is development-stage and has limited product sales, reported results can be affected materially by clinical trial spending, non-cash financing items, and the timing of government reimbursements. - **Fair value accounting for convertible debt** — Can create non-cash volatility in other income and net loss - **Government subaward revenue recognition** — Creates low and uneven revenue tied to trial spending - **Equity-linked instruments and dilution** — Impacts EPS, dilution, and financing flexibility - **Going concern disclosure** — Important for assessing liquidity and financial statement assumptions - Fair value changes on convertible debt can affect other income - Equity-linked securities create dilution and valuation complexity - Government subaward revenue depends on eligible research costs - Clinical trial spending drives period-to-period expense volatility - Going concern assessment affects financial statement presentation --- *Last updated: 2026-09-24T12:18:56.027872+00:00*